Kamada Ltd. (KMDA)
NASDAQ: KMDA · Real-Time Price · USD
9.19
+0.26 (2.91%)
At close: Mar 4, 2026, 4:00 PM EST
9.19
0.00 (0.00%)
After-hours: Mar 4, 2026, 4:10 PM EST
Kamada Employees
Kamada had 420 employees as of December 31, 2024. The number of employees increased by 42 or 11.11% compared to the previous year.
Employees
420
Change (1Y)
42
Growth (1Y)
11.11%
Revenue / Employee
$416,160
Profits / Employee
$48,676
Market Cap
525.32M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 420 | 42 | 11.11% |
| Dec 31, 2023 | 378 | -2 | -0.53% |
| Dec 31, 2022 | 380 | 25 | 7.04% |
| Dec 31, 2021 | 355 | -53 | -12.99% |
| Dec 31, 2020 | 408 | -21 | -4.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tilray Brands | 2,842 |
| Canopy Growth | 960 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 854 |
| Esperion Therapeutics | 304 |
| Ironwood Pharmaceuticals | 253 |
| Akebia Therapeutics | 181 |
| Aquestive Therapeutics | 142 |
KMDA News
- 7 weeks ago - Kamada 2025/2026 Outlook: Evaluating Revenue Growth And Product Drivers - Seeking Alpha
- 2 months ago - Kamada (KMDA) Projects Strong Revenue and EBITDA Growth by 2026 - GuruFocus
- 2 months ago - Kamada forecasts double-digit profitable growth in 2026 - Seeking Alpha
- 2 months ago - Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender - GlobeNewsWire
- 3 months ago - Kamada Ltd Corporate Update Call Transcript - GuruFocus
- 3 months ago - Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook - Benzinga
- 3 months ago - Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook - Benzinga
- 3 months ago - Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript - Seeking Alpha